Treatment Decision Regret Among Long-Term Survivors of Localized Prostate Cancer: Results From the Prostate Cancer Outcomes Study
Authors:
- Richard M. HoffmanRHRichard M. Hoffman
- Mary LoMLMary Lo
- Jack A. ClarkJCJack A. Clark
- Peter C. AlbertsenPAPeter C. Albertsen
- Michael J. BarryMBMichael J. Barry
- Michael GoodmanMGMichael Goodman
- David F. PensonDPDavid F. Penson
- Janet L. StanfordJSJanet L. Stanford
- Antoinette M. StroupASAntoinette M. Stroup
- Ann S. HamiltonAHAnn S. Hamilton
- 10 July 2017
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (20) , 2306-2314
Abstract
Purpose: To determine the demographic, clinical, decision-making, and quality-of-life factors that are associated with treatment decision regret among long-term survivors of localized prostate cancer. Patients and Methods: We evaluated men who were age ≤ 75 years when diagnosed with localized prostate cancer between October 1994 and October 1995 in one of six SEER tumor registries and who completed a 15-year follow-up survey. The survey obtained demographic, socioeconomic, and clinical data and measured treatment decision regret, informed decision making, general- and disease-specific quality of life, health worry, prostate-specific antigen (PSA) concern, and outlook on life. We used multivariable logistic regression analyses to identify factors associated with regret. Results: We surveyed 934 participants, 69.3% of known survivors. Among the cohort, 59.1% had low-risk tumor characteristics (PSA < 10 ng/mL and Gleason score < 7), and 89.2% underwent active treatment. Overall, 14.6% expressed treatment decision regret: 8.2% of those whose disease was managed conservatively, 15.0% of those who received surgery, and 16.6% of those who underwent radiotherapy. Factors associated with regret on multivariable analysis included reporting moderate or big sexual function bother (reported by 39.0%; OR, 2.77; 95% CI, 1.51 to 5.0), moderate or big bowel function bother (reported by 7.7%; OR, 2.32; 95% CI, 1.04 to 5.15), and PSA concern (mean score 52.8; OR, 1.01 per point change; 95% CI, 1.00 to 1.02). Increasing age at diagnosis and report of having made an informed treatment decision were inversely associated with regret. Conclusion: Regret was a relatively infrequently reported outcome among long-term survivors of localized prostate cancer; however, our results suggest that better informing men about treatment options, in particular, conservative treatment, might help mitigate long-term regret. These findings are timely for men with low-risk cancers who are being encouraged to consider active surveillance.Keywords
This publication has 50 references indexed in Scilit:
- Shared Decision Making — The Pinnacle of Patient-Centered CareNew England Journal of Medicine, 2012
- Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task ForceAnnals of Internal Medicine, 2011
- Demonstration of erectile management techniques to men scheduled for radical prostatectomy reduces long‐term regret: a comparative cohort studyBJU International, 2011
- Treatment decision‐making for localized prostate cancer: What younger men choose and whyThe Prostate, 2011
- The importance and complexity of regret in the measurement of ‘good’ decisions: a systematic review and a content analysis of existing assessment instrumentsHealth Expectations, 2010
- Patient Decision Aids for Prostate Cancer Treatment: A Systematic Review of the LiteratureCA: A Cancer Journal for Clinicians, 2009
- Guideline for the Management of Clinically Localized Prostate Cancer: 2007 UpdateJournal of Urology, 2007
- Regret of Treatment Decision and its Association with Disease-Specific Quality of Life Following Prostate Cancer TreatmentCancer Investigation, 2007
- The UCLA Prostate Cancer IndexMedical Care, 1998
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992